Tucatinib (Tucatinib) launch time in China

Tucatinib (Tucatinib) is an innovative targeted drug for HER2-positive breast cancer, developed by the American biopharmaceutical company Seattle Genetics (now Seagen). In December of 201912, tucatinib (tucatinib) was approved by the U.S. Food and Drug Administration ( FDA) for the treatment of patients with advanced or metastatic HER2-positive breast cancer, especially those who have received multiple other treatments. The efficacy and safety of tucatinib have been significantly verified in clinical trials.

As of now, tucatinib (tucatinib) has not been officially launched in China. Despite this, domestic breast cancer patients and the medical community are full of expectations for this drug, because tucatinib (tucatinib)'s successful experience and good reputation internationally make it regarded as a potentially important treatment option. Tucatinib (Tucatinib) is not currently on the market in China, so patients cannot purchase it domestically and need to purchase Tucatinib (Tucatinib) through overseas channels. There are original drugs and generic drugs abroad. Original drugs include European versions of original drugs, which cost tens of thousands of yuan and are very expensive. Foreign generic drugs include generic drugs from Laos and Bangladesh, which cost around three to four thousand yuan and have basically the same ingredients as the original drugs.

Global clinical trial results of tucatinib show that it is comparable to trastuzumab (Herceptin) and capecitabine (Capecitabine) Combined use, it can significantly improve the progression-free survival (PFS) and overall survival (OS) of patients with HER2 positive breast cancer. In the pivotal HER2CLIMB trial, patients who received tucatinib (tucatinib) combination therapy had a significant survival advantage compared with the control group. These data provide strong support for its approval and future application in China.

It is worth noting that tucatinib not only performs outstandingly in efficacy, but its safety and tolerability have also been fully recognized. Common adverse reactions include diarrhea, hand-foot syndrome, nausea, and fatigue, but most patients are able to effectively manage these side effects with dose adjustment and symptomatic treatment. This makes tucatinib (tucatinib) highly operable and patient-compliant during treatment.